DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mercaptopurine (Mercaptopurine) - Acute Myeloid Leukaemia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Acute Myeloid Leukaemia (26)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mercaptopurine where reactions include acute myeloid leukaemia. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Mercaptopurine side effects in 52 year old female

Reported by a physician from United States on 2012-07-23

Patient: 52 year old female

Reactions: Oesophageal Mass, Multi-Organ Failure, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of 3 + 7 regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: part of 3 + 7 regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in 25 year old male

Reported by a physician from United States on 2012-07-23

Patient: 25 year old male

Reactions: Acute Myeloid Leukaemia, Petechiae

Drug(s) suspected as cause:
Advil

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in 49 year old male

Reported by a physician from United States on 2012-07-23

Patient: 49 year old male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Fludarabine Phosphate
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Fludarabine Phosphate
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in female

Reported by a physician from United States on 2012-07-18

Patient: female

Reactions: Multi-Organ Failure, Oesophageal Mass, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of 3 + 7 regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Fludarabine Phosphate
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Advil

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in female

Reported by a physician from United States on 2012-07-18

Patient: female

Reactions: Oesophageal Mass, Multi-Organ Failure, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of 3 + 7 regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Fludarabine Phosphate
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Advil

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in female

Reported by a physician from United States on 2012-07-18

Patient: female

Reactions: Oesophageal Mass, Multi-Organ Failure, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of 3 + 7 regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Fludarabine Phosphate
    Dosage: part of flag-ida regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation; later received flag-ida regimen (pethema regimen)

Idarubicin HCL
    Dosage: part of flag-ida regimen

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Idarubicin HCL
    Dosage: 12 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg, unk
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2, unk
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Advil



Possible Mercaptopurine side effects in male

Reported by a physician from United States on 2012-07-18

Patient: male

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Advil

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in female

Reported by a physician from United States on 2012-07-18

Patient: female

Reactions: Multi-Organ Failure, Oesophageal Mass, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Chloroma, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Dosage: part of 3 + 7 regimen
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d on days 2, 4, 6, 8; later received during consolidation (pethema regimen)
    Indication: Myelodysplastic Syndrome

Idarubicin HCL
    Dosage: part of 3 + 7 regimen

Idarubicin HCL
    Dosage: 5 mg/m2/d on d1-4 of 1-m consolidation; then 12 mg/m2/d (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Idarubicin HCL
    Dosage: 12 mg/m2/d for 1-m consolidation (pethema regimen)

Mercaptopurine
    Dosage: 50 mg/m2/d (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2/w (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2/d on d1-5 of 1-m consolidation (pethema regimen)
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d; later received as maintenance therapy (pethema regimen)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2/d for 15d every 3m (pethema regimen)



Possible Mercaptopurine side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-17

Patient: male

Reactions: Anaemia, Acute Myeloid Leukaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Idarubicin HCL
    Dosage: 12 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg, unk
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in 52 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-17

Patient: 52 year old female

Reactions: Multi-Organ Failure, Oesophageal Mass, Acute Myeloid Leukaemia, Pancytopenia, Chloroma

Adverse event resulted in: death

Drug(s) suspected as cause:
Idarubicin HCL
    Dosage: 12 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg, unk
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2, unk
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m2, unk
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Other drugs received by patient: Cytarabine



Possible Mercaptopurine side effects in 55 year old female

Reported by a physician from United Kingdom on 2012-06-15

Patient: 55 year old female

Reactions: Acute Myeloid Leukaemia, Pancytopenia, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Vincristine Sulfate
    Indication: Acute Lymphocytic Leukaemia



Possible Mercaptopurine side effects in 52 year old female

Reported by a physician from United States on 2012-06-14

Patient: 52 year old female

Reactions: Multi-Organ Failure, Acute Myeloid Leukaemia, Chloroma

Adverse event resulted in: death

Drug(s) suspected as cause:
Idarubicin HCL
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL

Mercaptopurine
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in 25 year old male

Reported by a physician from United States on 2012-06-14

Patient: 25 year old male

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
ALL-Trans Retinoic Acid (Atra)
    Administration route: Oral

ALL-Trans Retinoic Acid (Atra)
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL

Idarubicin HCL

Mercaptopurine
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in 49 year old male

Reported by a physician from United States on 2012-05-29

Patient: 49 year old male

Reactions: Stem Cell Transplant, Refractory Anaemia With AN Excess of Blasts, Chromosome Analysis Abnormal, Acute Myeloid Leukaemia, Post Procedural Complication

Adverse event resulted in: death

Drug(s) suspected as cause:
(Granulocyte Colony Stimulating Factor)
    Indication: Refractory Anaemia

Cytarabine
    Indication: Refractory Anaemia

Fludarabine Phosphate
    Indication: Refractory Anaemia

Idarubicin HCL
    Dosage: 12 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m^2 per week
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone Hydrochloride
    Dosage: 10 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in 52 year old female

Reported by a physician from United States on 2012-05-29

Patient: 52 year old female

Reactions: Oesophageal Mass, Multi-Organ Failure, Gene Mutation, Acute Myeloid Leukaemia, Refractory Cytopenia With Multilineage Dysplasia, Chloroma

Drug(s) suspected as cause:
Cytarabine
    Indication: Refractory Cytopenia With Multilineage Dysplasia

Idarubicin HCL
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m^2 per week
    Indication: Acute Promyelocytic Leukaemia

Novantrone
    Dosage: 10 mg/m 2 milligram(s)/sq. metere
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in 25 year old male

Reported by a physician from United States on 2012-05-29

Patient: 25 year old male

Reactions: Stem Cell Transplant, K-RAS Gene Mutation, Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Idarubicin HCL
    Dosage: 12 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Dosage: 15 mg/m^2 per week
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone Hydrochloride
    Dosage: 10 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Dosage: 45 mg/m 2 milligram(s)/sq. meter
    Indication: Acute Myeloid Leukaemia



Possible Mercaptopurine side effects in 49 year old male

Reported by a individual with unspecified qualification from United States on 2012-05-22

Patient: 49 year old male

Reactions: Acute Myeloid Leukaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Idarubicin HCL
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Administration route: Oral

Tretinoin
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia



Possible Mercaptopurine side effects in 25 year old male

Reported by a individual with unspecified qualification from United States on 2012-05-22

Patient: 25 year old male

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Idarubicin HCL
    Indication: Acute Promyelocytic Leukaemia

Mercaptopurine
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Administration route: Oral

Other drugs received by patient: Ibuprofen (Advil)



Possible Mercaptopurine side effects in 52 year old female

Reported by a individual with unspecified qualification from United States on 2012-05-22

Patient: 52 year old female

Reactions: Acute Myeloid Leukaemia

Drug(s) suspected as cause:
Cytarabine
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL
    Indication: Acute Promyelocytic Leukaemia

Idarubicin HCL

Mercaptopurine
    Indication: Acute Promyelocytic Leukaemia

Methotrexate
    Indication: Acute Promyelocytic Leukaemia

Mitoxantrone
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Administration route: Oral
    Indication: Acute Promyelocytic Leukaemia

Tretinoin
    Administration route: Oral

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017